Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

Sep 06 2019

• By Malcolm Spicer

Related Content

Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval

Sep 04 2019

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

Aug 09 2019

Omega-3 Marketers Back Down On Comparisons To Amarin's Vascepa

May 10 2019

Amarin: Complaint Of Unfair Competition From Omega-3 Supplements 'Ripe' For Supreme Court

Aug 01 2019

Amarin Critic's Petition Counters Its Bid To Stop Some Omega-3 Supplement Sales

Aug 01 2019

FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More

Jun 19 2019

Omega-3 Heart Health Claims Decision: FDA Out Of Step With Industry?

Jul 01 2019

Related Companies

Amarin Corp plc

Additional Topics

Europe United States Dietary Supplements Regulation Commercial Business Strategies Advertising, Marketing & Sales Clinical Trials Companies Compliance Drug Approval Standards FDA Ingredients Legal Issues Manufacturing Policy Advisory Committees Cardiovascular Respiratory Consumer BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window